SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings is trending due to a confluence of factors including anticipation for upcoming earnings, potential government contracts related to drone and counter-UAS technology, and the recent acquisition of Sentrycs. The community is buzzing about the company's strategic positioning in the government tech spending sector and potential for a short squeeze. Increased trading volume and institutional interest are also fueling the conversation.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

ORCL is trending amid discussions about debt levels, insider selling, and concerns raised by Michael Burry regarding earnings quality, leading to caution among investors. The community is debating whether the recent dip presents a buying opportunity, especially with potential AI-driven margin increases on the horizon. News around AI buildouts, data center deals, and analyst target adjustments are adding to the mix.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending as investors discuss the potential impact of its upcoming earnings report, particularly in light of Singles Day sales data and a recent analyst downgrade. The community is weighing the company's valuation against its growth prospects and debating whether buybacks or AI initiatives will be highlighted. Sentiment is mixed, with some expressing frustration over the stock's performance relative to its peers.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Recent earnings reports are driving discussion around DIS, with community members dissecting revenue misses and subscriber growth in streaming services.  A key point of contention revolves around the company's content strategy and its impact on the brand's core values, with some investors expressing concern over perceived deviation from family-friendly entertainment. Despite these debates, upcoming film releases and potential for long-term growth are also being weighed.

Paysafe Ltd. provides online payment solutions. The firm operates through the following segments: Merchant Solutions and Digital Wallet. The Merchant Solutions business segment focuses on card not present and card present solutions for small to medium size business merchants. The Digital Wallet business segment provides wallet based online payment solutions through its Skrill, eCash solutions and NETELLER brands. The company was founded in 1996 and is headquartered in London, the United Kingdom.

Paysafe Limited

Paysafe Ltd

Paysafe is trending due to lowered guidance and concerns about management's credibility after recent earnings, sparking discussions about a potential take-private scenario and whether the company can turn things around. Community sentiment is largely negative, with many questioning the company's direction and expressing frustration with leadership's performance. The focus is on upcoming financial reports and the need for concrete evidence of improvement.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending due to the launch of the first spot XRP ETF on Nasdaq, with the community actively discussing its potential impact on price and institutional adoption. While some express excitement about potential inflows and a supply squeeze, others remain skeptical, drawing comparisons to previous ETF launches and pointing to ongoing market dynamics. Discussion also involves Ripple's partnerships and potential impact on XRP's broader utility in financial infrastructure.

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.

Mersana Therapeutics Inc

Mersana Therapeutics ($MRSN) is trending due to its acquisition by Day One Biopharmaceuticals ($DAWN) for up to $285 million, sparking discussion around the deal's structure, including cash and CVR components. The community is weighing the acquisition's value, potential short squeeze, and the implications for Day One Biopharmaceuticals. Some investors believe this deal is bullish for $DAWN while other comments focus on the high short interest and upcoming catalysts.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

BETR is trending as investors closely monitor earnings and strategic partnerships, anticipating updates on the company's pipeline and future profitability. Community members are actively debating potential price movements, especially in light of its low float and the possibility of a short squeeze, while also assessing the impact of broader market trends like mortgage demand and interest rates. Some are also taking notice of insider transactions.

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Korro Bio Inc.

Korro Bio Inc

Korro Bio ($KRRO) is trending due to a recent analyst downgrade from RBC Capital and disappointing clinical trial data, leading to a significant price target reduction. The community is discussing the company's cash position, potential for a rebound, and a paused partnership with Novo Nordisk. Some traders are considering it a "biggest loser play," while others believe it's oversold and presents a buying opportunity based on its cash reserves.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco's stock is trending following earnings and forward guidance that beat expectations, fueled by significant AI infrastructure orders. Community discussions revolve around analyst upgrades and the potential for further gains driven by AI and campus networking upgrades. Despite a strong earnings report, some analysts express caution, drawing parallels to past tech bubbles.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mersana Therapeutics To Be Acquired By Day One Biopharmaceuticals For Up To $285 Mln

(RTTNews) - Mersana Therapeutics, Inc. (MRSN), a biopharmaceutical company, Thursday, announced that it has entered a definitive agreement to be acquired by Day One Biopharmaceuticals through a...

<ul class="summary-bullets"><li>Day One will purchase Mersana for a total consideration of up to $55.25 per share.&nbsp;</li><li>The transaction is expected to close by the end of January 2026, and Day One expects to finance it with existing cash resources.&nbsp;</li><li>The acquisition will add antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) to Day One’s cancer portfolio.</li></ul>Day One Biopharmaceuticals, Inc. (DAWN) said on Thursday that it has signed a definitive merger agreement to acquire Mersana Therapeutics (MRSN) for up to $285 million to expand its oncology portfolio.Brisbane-based Day One will commence a tender offer to acquire all of the outstanding shares of Mersana common stock for $25 per share in cash at closing, in addition to a contingent value right that allows holders to receive up to an aggregate of $30.25 per CVR upon the completion of certain milestones for a total consideration of up to $55.25 per share.The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday. The transaction is expected to close by the end of January 2026, and Day One <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/13/3187097/0/en/Day-One-to-Acquire-Mersana-Therapeutics-to-Advance-Mission-to-Bring-New-Medicines-to-People-of-All-Ages-with-Life-Threatening-Diseases.html">expects</a> to finance it with existing cash resources.<a href="https://stocktwits.com/symbol/MRSN">MRSN shares</a> traded 200% higher in the pre-market session at the time of writing while <a href="https://stocktwits.com/symbol/DAWN">DAWN shares</a> dropped 12%.<h2 class="st-heading-2">Expanding Its Oncology Portfolio</h2>The acquisition will add antibody-drug conjugate (ADC) emiltatug ledadotin (Emi-Le) to Day One’s cancer portfolio. Emi-Le has demonstrated early anti-tumor activity in an ongoing early-stage study for an aggressive cancer called adenoid cystic carcinoma type-1.Day One believes that Emi-Le is well-positioned for potential rapid development and commercialization and expects its financial profile to aid the development of it through potential approval with no additional financing.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around MRSN jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.MRSN stock is down by 75% this year and by 87% over the past 12 months. Meanwhile, DAWN stock has lost 18% this year.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ford-gears-up-for-wider-bluecruise-rollout-across-europe-in-2026/cLP9TrNRE3g">Ford Gears Up For Wider BlueCruise Rollout Across Europe In 2026</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal

The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday.

Equity

Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates

Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.00% and -14.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Curis (CRIS) Reports Q3 Loss, Beats Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of +20.97% and +8.58%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of +5.41% and +1.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?

The mean of analysts' price targets for Mersana Therapeutics (MRSN) points to a 314.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Mersana Therapeutics (MRSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -8.80% and -58.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +29.82% and +181.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates

VistaGen Therapeutics (VTGN) delivered earnings and revenue surprises of 0.00% and -62.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

MRSN
Mersana Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MRSN News

MRSNMersana Therapeutics Inc